Medicare Drug Price Talks Could Drive More Patient-Reported Data

Medicare’s drug price negotiations could advance broader use of the patient experience into drug development if there’s more clarity on what to submit and the level of impact it will have.

The patient experience is one of several factors the Centers for Medicare & Medicaid Services will consider as the agency prepares to negotiate drug prices for the first time, according to initial guidance published last month to lay out how the negotiation process will work.

Specifically, patient experience will contribute to the evaluation of a drug’s clinical benefit compared with therapeutic alternatives. The agency also said it will consider ...